NRx Pharmaceuticals (NASDAQ:NRXP) Coverage Initiated at BTIG Research

Analysts at BTIG Research initiated coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Wednesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $18.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. D. Boral Capital restated a “buy” rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $28.25.

NRx Pharmaceuticals Price Performance

Shares of NRx Pharmaceuticals stock opened at $1.91 on Wednesday. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The stock has a 50-day simple moving average of $2.50 and a 200-day simple moving average of $2.05. The firm has a market cap of $32.24 million, a price-to-earnings ratio of -0.89 and a beta of 1.22.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, equities research analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Trading of NRx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Townsquare Capital LLC bought a new position in NRx Pharmaceuticals during the third quarter worth about $25,000. Sassicaia Capital Advisers LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $33,000. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $56,000. Millennium Management LLC acquired a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $61,000. Finally, Anson Funds Management LP bought a new position in NRx Pharmaceuticals in the third quarter valued at approximately $241,000. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.